  Hyperinflation refers to the increasing cost of drugs which occurs due to continued drug shortages and rebranding. Hyperinflation has significant implications in increasing overall healthcare costs with reduced reimbursement , increased patient acuity , and an aging population , but published strategies to reduce costs and minimize waste are limited. To describe the hyperinflation and cost mitigation strategies of three vasopressor medications , vasopressin , epinephrine , and ephedrine. The steep increase in medications is expected to continue , and mitigation strategies to reduce waste and select the most cost effective therapy to offset the price increase is crucial for healthcare systems.